As innovation in clinical diagnostics accelerates, collaboration is becoming increasingly essential to ensure new tools reach the clinicians and patients who need them most. Mary Jo Williamson, chief administrative officer at Mayo Clinic Laboratories, discusses how a strategic approach to collaboration is helping build a more connected diagnostic ecosystem and enabling more comprehensive care.

Q: Why are strategic collaborations so critical in today’s diagnostics landscape?

A: The volume and pace of innovation in diagnostics today are extraordinary, but no single organization can bring all of those advances to patients on its own. Strategic collaboration allows us to connect with like-minded innovators and expand access to important new diagnostic capabilities.

At Mayo Clinic Laboratories, everything starts with the patient. Collaborating with others helps ensure that patients and providers can benefit from advances happening across the broader healthcare landscape, not just within one organization.

Q: What defines a strong strategic collaboration in diagnostics?

A: It begins with alignment. We look for organizations that share our commitment to quality, safety, and putting patients first. That alignment creates a strong foundation for trust, which is essential in healthcare.

Equally important is having a clear and complementary value proposition. The most effective collaborations bring together distinct strengths to solve real clinical needs, whether that’s expanding access to specialized testing or enhancing how diagnostics are used in care decisions. Finally, it has to be mutually beneficial. When both organizations are gaining value, it fosters shared purpose and long-term commitment.

Q: How do these collaborations translate into value for clinicians?

A: Strategic collaboration makes it easier for clinicians to access a broader range of diagnostic insights without added complexity. Instead of navigating multiple relationships or systems, they can rely on a more connected experience.

Just as importantly, collaboration helps refine how diagnostics are used. By working closely with innovators, we can better understand where and how specific tests add the most value, which ultimately supports more informed clinical decision-making.

Q: What impact do collaborations have on innovation itself?

A: Collaboration accelerates innovation in a very practical way. It helps bring new diagnostics into clinical use more quickly by connecting developers with established infrastructure and clinical expertise.

It also creates a feedback loop. As diagnostic tools are used in real-world settings, we gain insights that can inform improvements, new applications, and even entirely new areas of development. That continuous exchange is what drives meaningful progress.

Q: What does it take to sustain successful collaborations over time?

A: Ongoing relationship management is key. It’s important to establish clear expectations from the beginning and revisit them regularly as needs evolve. Healthcare is constantly changing, so partnerships must be adaptable.

Data also plays an important role. Regular performance reviews and open, transparent conversations help ensure that collaborations continue to deliver value and remain aligned with shared goals.

Q: Looking ahead, how will strategic collaboration shape the future of diagnostics?

A: The future of diagnostics will be increasingly connected. Strategic collaboration is what enables us to bring together diverse innovations into a more cohesive ecosystem that supports clinicians and patients.

By continuing to work with organizations that share our values and commitment to patient care, we can expand access to new capabilities, improve how diagnostics inform decisions, and ultimately help deliver more comprehensive, patient-centered care.